Abstract:Background: Developing guidelines for the diagnosis and treatment of common cancers in China based on the evidence-based practice, the availability of diagnosis and treatment products, and the up-to-date advances in precision medicine is one of the basic tasks of the Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) Committee. Methods: Protocols with high evidence level and good availability are used as the Level I recommendations; protocols with relatively high evidence level but slightly lower expert consensus or with poor availability are used as the Level II recommendations; and protocols that are clinically applicable but with low evidence level are regarded as the Level III recommendations. Based on the findings of clinical research at home and abroad and the opinions of CSCO BC experts, the CSCO BC guidelines determine the levels of recommendations for clinical application. Results: For human epidermal growth factor receptor 2 (HER2)-positive breast cancer, a combination of trastuzumab and pertuzumab regimen were recommended as Level I recommendation for neoadjuvant and first line metastatic breast cancer. Pyrotinib is also recommended as Level I recommendation in first line and second line therapy according to the latest studies conducted in China. Antibody drug conjugates was also recommended for patients with trastuzumab progression. For triple negative breast cancer, immunotherapy in early and metastatic breast cancer was highlighted and listed as new chapters in this version of guideline. For hormone receptor (HR)-positive breast cancer, cyclin dependent kinase 4/6 (CDK4/6) was recommended in different stages, especially in adjuvant therapy. There was also a new chapter for HER2-low breast cancer stratified by HR status. Conclusions: We firmly believe that evidence-based, availability-concerned, and consensus-based guidelines will be more feasible for clinical practice in China and in other countries with similar situations.

Update in Version 2021 of CSCO Guidelines for Colorectal Cancer from Version 2020

CSCO Guidelines for Colorectal Cancer Version 2024: Updates and Discussions.

Updates in Version 2019 of CSCO Guidelines for Colorectal Cancer from Version 2018.

Interpretation of Updated Guidelines for Colorectal Cancer Screening in Average-Risk Individuals in the United States

CSCO Guidelines for Colorectal Cancer Version 2022: Updates and Discussions

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023

[Chinese Protocol of Diagnosis and Treatment of Colorectal Cancer (2023 edition)].

Chinese national clinical practice guidelines on prevention, diagnosis and treatment of early colorectal cancer

The Current Status of Treatment for Colorectal Cancer in China

CSCO guidelines for metastatic colorectal cancer: personalized medicine in clinical practice

Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) Guidelines in 2024: International Contributions from China

Chinese society of clinical oncology (CSCO) Breast Cancer Guidelines 2022

National Guidelines for Diagnosis and Treatment of Colorectal Cancer 2020 in China (english Version)

Current status of rectal cancer treatment in China

Interpretation of CSCO melanoma guidelines 2020

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021

New opinions of colorectal cancer in 2010

Current status of surgical treatment of rectal cancer in China

Diagnostic and Therapeutic Strategy Updates of Rare Oncogenic Mutations in Chinese Society of Clinical Oncology Guidelines on Diagnosis and Treatment of Non-small Cell Lung Cancer (2023 Edition)

Interpretation of Japanese Society for Cancer of Colon and Rectum (JSCCR) guidelines 2014 for the treatment of colorectal cancer

Chinese Society of Clinical Oncology (CSCO) Breast Cancer guidelines 2024